Specificity and Sensitivity of Radioimmunoassay for Hepatitis B Antigen

GILBERT R. IRWIN, ALFRED M. ALLEN, WILLIAM H. BANCROFT, MILTON WILLHIGHT, AND PHILIP K. RUSSELL

Division of Communicable Diseases and Immunology, Department of Virus Diseases, and Division of Preventive Medicine, Walter Reed Army Institute of Research, Washington, D.C. 20012

Received for publication 19 June 1974

Sera from a survey of 6,026 people were tested for hepatitis B surface antigen by using radioimmunoassay and counter electrophoresis. Forty-eight sera (0.79%) were positive by counter electrophoresis and 152 sera (2.52%) were positive by radioimmunoassay, using the most liberal of the recommended criteria for positivity (i.e., counts 3 standard deviations above the mean). Absorption tests performed on the 152 radioimmunoassay-positive sera showed that 10 (6.6%) were false-positive reactions to guinea pig protein, 74 (48.6%) were due to false-positive reaction(s) with other protein(s) in the test system, and 68 (44.8%) were true positives. There was a strong correlation between the degree of elevation of radioactive counts and the proportions of sera that were true positives; all 49 sera with counts > 50 standard deviation units above the mean were true positives, but only 19 (18.4%) of the 103 sera with counts < 50 standard deviation units were true positives. A few sera with high counts required absorption with type-specific (type D) anti sera. The following conclusions were reached from this study: (i) absorption tests should be run on all radioimmunoassay-positive, counter electrophoresis-negative sera; (ii) most (about 90%) false positives are not due to anti-guinea-pig protein reactions; and (iii) radioimmunoassay, in combination with absorption tests, yields a modest increase (about 35%) in detection of true positives over use of counter electrophoresis alone.

Solid-phase radioimmunoassay (RIA) is one of the most sensitive and convenient techniques for detecting hepatitis B antigen (HB₄Ag) in serum (4). An unresolved problem in the use of this technique is the lack of consensus on the level of radioactivity in counts per minute that constitutes a positive test. A further difficulty has been reported recently by Sgouris (9), Prince (8), and Alter (2), who have demonstrated that many sera that are positive by RIA but negative by counter electrophoresis (CEP) are false-positive reactions due to nonspecific human antibody against guinea pig proteins used in the test system. Resolution of these problems is required to avoid misclassification of sera tested by RIA. This survey reports efforts to determine the sensitivity and specificity of RIA, by using the Ausria kit (Abbott Laboratories, N. Chicago, Ill.), for HB₄Ag in the largest collection of sera reported.

1 Present address: Letterman Army Institute of Research, San Francisco, Calif.

MATERIALS AND METHODS

Source of sera. The sera used in this study were obtained during a serologic survey for HB₄Ag, which was conducted at Fort Hood, Texas during February and March of 1973. The survey was part of an investigation of an outbreak of viral hepatitis in soldiers (A. M. Allen and G. R. Irwin, unpublished data). Sera were collected from 6,026 military and civilian personnel with no signs or symptoms of hepatitis. In addition, sera were obtained from 85 patients with acute hepatitis.

HB₄Ag tests. The solid-phase radioimmunoe assay for HB₄Ag (Ausria kit from Abbott Laboratories, N. Chicago, Ill.) was performed as described by Ling and Overby (7). The Ausria kits used were those commercially available from June 1972 through May of 1973. These kits did not contain cold guinea pig serum in the ¹²⁵I-labeled guinea pig anti-hepatitis B antigen. Briefly, 0.1 ml of serum to be tested was placed in plastic tubes coated with guinea pig anti-hepatitis B₄ (anti-HB₄) and incubated for 16 h at room temperature. Each tube was washed with five 2-ml samples of tris(hydroxymethyl)aminomethane buffer. After thorough aspiration of the remaining buffer from the bottom of the tube, 0.1 ml of ¹²⁵I-labeled guinea pig
anti-HB$_v$ was added and incubated for 90 min at room temperature, and the tubes were washed as described above and counted in a model 1185 Searle (Nuclear-Chicago Corp., Des Plains, Ill.) gamma counter. The manufacturer's negative control serum was dispensed 10 times into separate tubes and processed as above for all runs. All CEP-positive sera were checked for HB$_v$Ag specificity by immunodiffusion against rabbit anti-HB$_v$, and standard HB$_v$Ag. CEP-positive sera were considered HB$_v$Ag-positive if lines of identity with standard HB$_v$Ag were obtained.

**Absorption tests for HB$_v$Ag specificity.** Sera positive by RIA (i.e., count per minute 3 standard deviations [SD] above the mean of 10 replicates of the negative control; or according to the Abbott criteria, 2.1 times the mean of negative control sera) and negative by CEP were analyzed for specificity to HB$_v$Ag by means of the following absorption test. Samples of 0.1 ml of the serum to be tested were incubated at room temperature for 2 h with 0.025 ml of each of four absorption sera, normal guinea pig serum, guinea pig anti-HB$_v$, normal rabbit serum, and rabbit anti-HB$_v$. In duplicate, samples were run without absorption. After incubation, a 0.1-ml amount of the absorbed serum was pipetted into Atria tubes and processed as above. Since rabbit and guinea pig anti-HB$_v$ had been shown to decrease radioactive counts of CEP-positive sera by 80% or more, RIA-positive and CEP-negative sera showed a decrease in counts per minute in excess of 80% with rabbit or guinea pig anti-HB$_v$ (but not by normal rabbit or guinea pig sera) were considered specific for HB$_v$Ag.

**RESULTS**

**Sensitivity.** The sera obtained from 6,026 asymptomatic subjects at Fort Hood were tested for HB$_v$Ag by RIA and CEP (Table 1). According to one's choice of three recommended criteria for RIA-test positive (5, 7), RIA was 2.2, 2.5, or 3.2 times more sensitive than CEP (positive RIA test: 2.1 times the mean, 5 SD above the mean, or 3 SD, respectively). The manufacturer's criteria of 2.1 times the mean ranged between 4.4 and 13.6 SD units on 38 runs and averaged 8.3 SD units.

**HB$_v$Ag specificity.** The 152 sera which were positive by RIA were tested for specific reactivity for HB$_v$Ag. Each of the 48 sera which were positive by CEP (as well as by RIA) gave precipitin lines of identity with HB$_v$Ag standards used for subtyping with rabbit antisera.

Absorption tests were performed to determine the specificity of RIA-positive, CEP-negative sera for HB$_v$Ag. The sera were classified as true or false positives according to the following criteria: (i) true positive sera, sera showing an 80% or more decrease in counts per minute after absorption with guinea pig or rabbit anti-HB$_v$, but not with normal animal sera, (ii) false-positive anti-guinea pig protein, sera blocked by normal guinea pig serum; and (iii) indeterminate false-positive, sera inhibited by neither specific anti-HB$_v$ nor by normal animal sera. The latter form of false positive was labeled indeterminate because its mechanism is unknown, but the former was referred to as anti-guinea pig protein to indicate nonspecific reactivity to guinea pig protein used in the test.

Examples of the results obtained after absorption testing are shown together with their interpretation in Table 2.

With the criteria outlined above, 68 (44.8%) of the 152 RIA-positive sera were classified as true positive, 10 (6.6%) were false positives (anti-guinea pig protein), and 74 (48.6%) were indeterminate false positives. Fifty-five (74%) of the sera classified as indeterminate false positives had radioactivity counts between 3 SD units above the mean and 2.1 times the mean of the negative control. The counts in this range were too low to yield conclusive results with absorption tests. Fourfold concentration of six of these sera failed to resolve the problem, primarily because the counts did not show a proportionate increase with concentration.

Four RIA-positive, CEP-negative sera with radioactivity counts greater than 20 SD units above the negative control mean were not inhibited by animal sera containing anti-HB$_v$ specific for subtype Y. Repeat testing with sera containing anti-HB$_v$ against subtype D showed significant inhibition. Unabsorbed serum showed 5,554 counts/min, and normal guinea pig serum showed 3,864 counts/min. Guinea pig HB$_v$Ab serum specific for subtype Y showed 3,174 counts/min, and the guinea pig HB$_v$Ab serum specific for subtype D showed 630 counts/min.

There was a correlation between the degree of

**Table 1. Hepatitis B antigen positivity in sera from 6,026 asymptomatic people testing with RIA and CEP**

| Test results | Subjects |
|--------------|----------|
| CEP          | RIA      |
| Positive     | Counts/min > 3 SD* | 48 | 0.79 |
| Negative     | Counts/min > 2.1 x m' | 56 | 0.93 |
| Negative     | 2.1 x m > counts/min | 15 | 0.25 |
|             | 5 SD     | 33 | 0.55 |
|             | 5 SD > counts/min | 3 SD |

* Based on radioactivity in counts per minute.
* SD, Standard deviations above the mean of the negative control.
* m, Mean of the negative control.
TABLE 2. Absorption of RIA-positive sera to determine specificity for hepatitis B antigen/representative test results in counts per minute (employing Ausria kits)

| Serum no. | Unabsorbed sera | Absorbed sera | Interpretation |
|-----------|-----------------|---------------|----------------|
|           | CEP | RIA | Normal guinea pig serum | Guinea pig HBAb | Normal rabbit serum | Rabbit HBAb | |
| 032       | Positive | 10,051 | 8,352 | 826 | 8,600 | 852 | True positive |
| F 80      | Negative | 7,263 | 7,650 | 1,049 | 5,430 | 287 | True positive |
| F 1226    | Negative | 1,372 | 422 | 452 | 1,329 | 1,388 | False positive (anti-guinea pig protein) |
| F 1769    | Negative | 1,883 | 472 | 399 | 1,295 | 838 | False positive (anti-guinea pig protein) |
| M 744     | Negative | 739 | 775 | 794 | 863 | 728 | Indeterminate false positive |
| M 1895    | Negative | 518 | 383 | 428 | 646 | 594 | Indeterminate false positive |
| Positive control (rabbit anti-guinea pig protein) | 16,175 | 511 | 492 | 13,461 | 16,256 | False positive (anti-guinea pig protein) |

Elevation of radioactivity counts found on RIA testing and the proportion of tests classified as true or false positives after absorption testing (Table 3). The higher the counts in SD units above the mean of the negative control, the more likely were the sera to be truly positive. All of the 49 sera with counts above 50 SD units were classified as true positives, while only 19 (18.4%) of the 103 sera with counts between 3 and 50 SD units were so classified. Seventy-two percent of the true positive sera had counts per minute in excess of 50 SD units.

Sensitivity and specificity in patients versus asymptomatics. The sensitivity and specificity of the RIA test for HBAg in sera obtained from asymptomatic people was compared to that in sera obtained from patients with acute hepatitis (Table 4). As compared to the results of CEP testing, RIA appeared to be relatively more sensitive in asymptomatic individuals than in patients; however, the difference was not statistically significant (χ² = 0.5, P > .25), and the average increase in sensitivity over CEP for patients as well as asymptomatics was 27%. No nonspecific reactions for HBAg occurred in patients.

DISCUSSION

The solid-phase RIA is reported to be up to 500 times more sensitive than CEP for detecting HBAg in serial dilutions of known positive sera (4). Used as a screening test in blood donors, RIA has detected as many as 10 times the number of positives detected by CEP (8). Recently, most of this apparent difference in sensitivity has been found to be due to nonspecific reactions to guinea pig and other proteins in the test system (1, 10), and revised estimates of sensitivity now indicate that RIA will detect only two to three times the number of true positives as CEP. Our results suggest that the actual difference in sensitivity is much more modest, being only on the order of 25% greater than CEP. Whether the discrepancy between our results and those of others is due to differences in technique or in the populations sampled remains to be determined.

Abbott Laboratories has recently modified the RIA kit by adding guinea pig serum to the radioactive labeled anti-HB (6). It is hoped that by this step the problem with nonspecific reactivity to guinea pig protein will be overcome. Although we have limited experience...
with the new test system, the data in this report suggest that its use would have resulted in only a 10% decrease in the number of false positives detected by RIA.

The majority of false-positive reactions appear to be what we have called indeterminate false positives. The exact cause of this reaction is unknown, but it is presumably due to other serum components within the test system. In this survey, none of 49 asymptomatic subjects whose sera were initially classified as indeterminate false positive had abnormal test results when rebled 3 months later. In contrast, each of seven subjects who were classified as anti-guinea pig false positive was RIA positive 3 months later, and 28 (90%) of 31 true positive asymptomatics were again RIA positive after 3 months. These findings indicate that the factors responsible for indeterminate false-positive tests were transient in their occurrence and may be due to temporally associated phenomena in the host or in the test system. A new RIA test from Abbott Laboratories, Ausrria II, appears to significantly decrease this second type of false-positive reaction by altering time and temperature of incubation from 16 h at room temperature to 2 h at 45°C (personal communication). In addition, the 125I-labeled anti-HBc is of human origin. The Ausrria II test appears to be an improved RIA test for detecting HBcAg, particularly for blood banks.

Absorption tests may occasionally show that sera which are strongly positive by RIA but negative by CEP cannot be inhibited either by normal guinea pig serum or by guinea pig anti-HBc. In this study and in at least one other (4), the cause was found to lie in subtype specificity of the anti-HBc used in the inhibition tests. Sera containing subtype Y may be missed unless subtype-specific antisera are used; most commercial antisera are usually satisfactory for subtype D (6). RIA-positive and CEP-negative sera with relatively low radioactivity counts (counts/min 2.1 × mean) are difficult to subtype by absorption-inhibition testing because of weak reactivity. However, when inhibition of sera with elevated counts per minute can be obtained by anti-HBc-differing specificities (anti-ayw versus anti-adw), it is possible to confirm not only the presence of HBcAg, but to suggest that the individual serum was of the subtype inhibited by the appropriate anti-HBc. Theoretically, it may be possible to distinguish HBcAg determinants W and R by this method (3).

For research purposes, our laboratory used 3 SD units above the mean on two different occasions as the criterion of a positive RIA test. Sera that were negative by CEP then underwent absorption tests for specificity. However, the results of specificity testing can largely be inferred from the RIA-test result itself (Table 3): high radioactivity counts (>50 SD above the mean) provide reasonable assurance that the serum is a true positive, but low counts (<20 SD above the mean) indicate the strong probability that the serum is a false positive.

With serially diluted CEP-positive sera, HBcAg can be routinely detected to the level of 10⁻⁴ or 10⁻⁵ by using the criterion of 3 SD above the mean to indicate of HBcAg. However, an individual serum obtained from a clinical source having counts per minute equal to points on a standard HBcAg titration curve cannot be assumed to contain HBcAg without specificity testing.

The need for further evaluation refinement of the RIA test for HBcAg is obvious. However, it remains the most sensitive of the available tests, and the problems of specificity can be overcome by means of appropriate procedures.

ACKNOWLEDGMENTS

We thank Col. John Moyar and his staff at Fort Hood for help in collecting sera, and we also extend our appreciation to Jerome Karwacki, Robert Pinkerton, Hubert Cannon, and Hobb Brown for technical assistance.

LITERATURE CITED

1. Alter, H. H., H. F. Polisky, P. V. Holland. 1972. False-positive test for hepatitis-associated antigen in blood donors caused by antibodies to ruminant serum protein. J. Immunol. 108:358-369.

2. Alter, H. H., P. V. Holland, R. H. Purcell, and J. L. Gerin. 1973. The Austria test: critical evaluation of sensitivity and specificity. Blood 42:947-957.

3. Bancroft, W. H., F. K. Mundon, and P. K. Russell. 1972. Detection of additional determinants of hepatitis B antigen. J. Immunol. 109:842-848.

4. Cossart, Y. E., E. Boxall, and T. H. Flewitt. 1973. False-negative radioimmunoassay test for Australia antigen. Lancet 2:1333-1334.

5. Ginsberg, A. L., M. E. Conrad, W. H. Bancroft, L. M. Ling, and L. R. Overby. 1972. Prevention of endemic HAA-positive hepatitis with gamma globulin. New Engl. J. Med. 286:562-567.
6. Leers, W. D., and G. M. Kouroupis. 1973. RIA kit for assay of hepatitis-B antigen. Lancet 3:1334–1335.
7. Ling, C. M., and L. R. Overby. 1972. Prevalence of hepatitis B virus antigen as revealed by direct radioimmunoassay with 125 I-antibody. J. Immunol. 109:834–841.
8. Prince, A. M., B. A. Brotman, B. A. Jass et al. 1973. Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet 2:1346–1350.
9. Sgouris, J. T. 1973. Limitations of the radioimmunoassay for hepatitis B antigen. New Engl. J. Med. 288:160–161.
10. Vyas, G. N., S. G. Aldelberg, and H. A. Perkins. 1973. Nonspecificity of hepatitis B antigen detected with iodine-125 labeled antibody. Science 182:1368–1369.